BELLUS Health to Present at the Eleventh International Virtual Cough Symposium
January 14 2021 - 7:00AM
Business Wire
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the
“Company”), a clinical-stage biopharmaceutical company developing
novel therapeutics for the treatment of refractory chronic cough
and other hypersensitization-related disorders, today announced
that Dr. Catherine Bonuccelli, M.D., BELLUS Health's Chief Medical
Officer, and Dr. Denis Garceau, Ph.D., Bellus Health’s Senior Vice
President of Drug Development, will be presenting data on BLU-5937
at the Eleventh International Virtual Cough Symposium being held on
January 21-22, 2021.
Oral Presentations:
Title: Results of RELIEF, a Phase 2a study with BLU-5937
in Refractory Chronic Cough Details: The presentation will
highlight nominal effect size and baseline characteristics of the
ITT population in the RELIEF trial, as well as for two
pre-specified sub-groups (≥20 coughs per hour at baseline and ≥32
coughs per hour at baseline). Session: Clinical trials of
antitussive therapies Date: Friday, January 22 Time:
1:00 – 3:30 p.m. GMT / 8:00 – 10:30 a.m. EST
Title: BLU-5937, A Potent and Selective P2X3 Receptor
Antagonist, Presents a Promising New Approach for the Treatment of
Chronic Pruritus in Atopic Dermatitis Patients Details: The
presentation will highlight preclinical data that support the
potential efficacy of P2X3 antagonists in the treatment of atopic
dermatitis-derived pruritus. Session: Migraine, itch and
chronic cough (Q&A session) Date: Friday, January 22
Time: 3:45 – 5:00 p.m. GMT / 10:45 – 12:00 p.m. EST
Following the conference, the presentations will be available in
the “Scientific Publications” section of BELLUS Health's website at
www.bellushealth.com.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company
developing novel therapeutics for the treatment of refractory
chronic cough and other hypersensitization-related disorders. The
Company's product candidate, BLU-5937, is being developed for the
treatment of refractory chronic cough and chronic pruritus.
Chronic cough, the lead indication for BLU-5937, is a cough
lasting more than eight weeks and is associated with significant
adverse physical, social and psychosocial effects on health and
quality of life. It is estimated that approximately 26 million
adults in the United States suffer from chronic cough with
approximately 3 million having refractory chronic cough lasting for
more than a year and approximately 6 million having refractory
chronic cough lasting more than 8 weeks and under one year. There
is no specific therapy approved for refractory chronic cough and
current treatment options are limited.
Chronic pruritus, commonly known as chronic itch, is an
irritating sensation that leads to scratching, and persists for
longer than six weeks, which can be debilitating and has a
significant impact on quality-of-life. It is a hallmark of many
dermatologic disorders, including atopic dermatitis (AD). It is
estimated that chronic pruritus associated with AD affects more
than 16.9 million adults in the United States.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210114005220/en/
Danny Matthews Director, Investor Relations and Communications
danny@bellushealth.com
Media: Julia Deutsch Solebury Trout
jdeutsch@soleburytrout.com
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Mar 2024 to Apr 2024
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Apr 2023 to Apr 2024